Calif. exemption changes nuclear medicine tech scope of practice
AuntMinnie
JANUARY 10, 2025
The state of California now allows certified nuclear medicine technologists to administer any radiopharmaceuticals for therapeutic purposes.
Bracco Imaging radiopharmaceutical firm Blue Earth Therapeutics raises nearly $77M
Radiology Business
OCTOBER 31, 2024
Leaders said the funding will help Blue Earth to further advance its development of PSMA-targeted therapies for prostate cancer.
Join 5,000
Insiders
Sign Up for our Newsletter
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Trending Sources
Nuclear Regulatory Commission warns of medical mishaps stemming from radiopharmaceutical use
Radiology Business
SEPTEMBER 10, 2024
NRC estimates that 29 of these “medical events” occurred between 2021 and 2023, with “many” involving new therapeutic radiopharma procedures.
Novartis to acquire radiopharmaceutical firm Mariana Oncology for up to $1.75B
Radiology Business
MAY 3, 2024
The Swiss drugmaker said the deal will bolster its research infrastructure and clinical supply capabilities, with an eye toward improving oncologic care.
ARRS: How to manage the side effects of radiopharmaceuticals
AuntMinnie
MAY 8, 2024
Theranostics treatments are used with increasing frequency now since the approvals and expansions of Lutathera (lutetium-177 [Lu-177]) DOTATATE, a radiopharmaceutical for neuroendrocrine tumors (NETs) and Pluvicto, Lu-177 PSMA-617, for prostate cancer.
Eli Lilly inks deal worth over $1.1B to develop new radiopharmaceuticals
Radiology Business
MAY 21, 2024
The Indianapolis-based drugmaker can hit the hefty total by reaching certain clinical, regulatory and commercial milestones.
Radiopharmaceutical firm Pentixapharm raises $22M through initial public stock offering
Radiology Business
OCTOBER 7, 2024
Founded in 2019, the firm is focused on developing products for the diagnosis and therapy of blood cancers and other indications not addressed by nuclear medicine.
Radiopharmaceutical firm Aktis Oncology raises $175M in Series B financing
Radiology Business
OCTOBER 1, 2024
The Boston clinical stage biotechnology company is working to develop new products to treat a range of solid tumors.
CMS proposes issuing separate payment for diagnostic radiopharmaceuticals in 2025
Radiology Business
JULY 12, 2024
For years, the agency has packaged payment for nuclear imaging agents with the procedure, but this has created a barrier for those who require pricier new drugs.
Generative AI, radiologist shortages feature in 2024 Minnies
AuntMinnie
NOVEMBER 12, 2024
With 100% of precincts now reporting, we’re finally ready to declare this year’s winners in our annual awards program recognizing excellence in radiology. The voters also zeroed in on the ongoing shortage of radiologists as the Biggest Threat to Radiology. Most Influential Radiology Researcher Minnies 2024 Winner: Erik H.
Radiologist 
360
360 
Lantheus lands rights to budding radiopharmaceuticals for initial outlay of $35M
Radiology Business
JUNE 28, 2024
One of the largest radiopharma companies in the world is acquiring global rights to a pair of novel therapeutic and diagnostic drugs used to target a peptide receptor overexpressed in prostate and breast cancers.
Radiopharmaceutical firm Telix investing up to $171M to acquire portfolio of imaging agents
Radiology Business
NOVEMBER 20, 2024
The Australian company will secure exclusive worldwide rights to a suite of diagnostic and therapeutic candidates geared toward urological cancers.
Imaging agent developer Telix to buy RLS radiopharmaceutical network for up to $250M
Radiology Business
SEPTEMBER 23, 2024
RLS operates America’s only Joint Commission-accredited radiopharmacy network, with 31 locations covering over 85% of the U.S. population.
Startup radiopharmaceutical developer Mariana Oncology raises $175M in series B financing
Radiology Business
SEPTEMBER 11, 2023
The company has developed a portfolio of nuclear medicine solutions including "lead candidate" MC-339, used for treating small cell lung cancer.
Nuclear Medicine 261
261 
Italian research team shows the way on sustainability
AuntMinnie
FEBRUARY 26, 2025
Additionally, modalities like MRI, CT, bone scans, and PET-CT are significant contributors to greenhouse gas emissions, with radiology accounting for approximately 1% of global healthcare-related emissions. The analysis might help to establish a model for balancing clinical and environmental priorities in radiology departments globally.
Bone Scan 130
130 
Radiopharmaceutical startup raises $56M in series A financing from GE HealthCare, Mayo Clinic
Radiology Business
OCTOBER 18, 2023
Nucleus RadioPharma will use the money to establish manufacturing facilities—with one located in Rochester, Minnesota, near Mayo—and build new technology for distribution.
CMS seeks feedback on issuing separate payment for diagnostic radiopharmaceuticals
Radiology Business
JULY 14, 2023
The agency issued its solicitation as part of the 2024 Hospital Outpatient Prospective Payment System proposed rule, released late Thursday.
After IPO fails, imaging agent developer Telix Pharmaceuticals raises $429M via debt
Radiology Business
JULY 23, 2024
The Melbourne, Australia-based radiopharmaceutical firm plans to use the proceeds to accelerate development of products in its theranostics portfolio
Pharmaceutical 292
292 
Medicare to boost payment for certain diagnostic imaging agents
Radiology Business
NOVEMBER 5, 2024
CMS is moving forward with a proposal to issue separate reimbursement for radiopharmaceuticals—a change long lobbied for by the imaging industry.
The rise of theranostics: Part 5 -- Advice from center administrators
AuntMinnie
JULY 12, 2024
Reshaping the hospital's nuclear medicine and radiopharmaceutical strategy toward theranostics involves intensive and inclusive planning, Beyder explained at SNMMI. Theranostics offers hospital radiology departments the opportunity to keep more reimbursement dollars in the department, Beyder explained.
Nuclear Medicine 264
264 
IMV: PET scan volumes continue to grow
AuntMinnie
MARCH 7, 2024
In terms of 2023 spending, the average radiopharmaceutical expenditure per fixed PET site is estimated to be $517,000. In 2023, 38% of PET systems were operated by the PET department, 28% by nuclear medicine, 24% by radiology/imaging, 5% by radiation oncology, and 2% by molecular imaging.
PET Scan 290
290 
The rise of theranostics: Part 3 -- What is a theranostics center?
AuntMinnie
JUNE 3, 2024
With therapeutic radiopharmaceuticals coming to market quickly and available to smaller institutions around the U.S., My vision of a theranostic center includes a flagship facility that has a PET/CT scanner, a SPECT/CT scanner, and then multiple rooms for infusions of radiopharmaceuticals," Siegel explained.
Nuclear Medicine 264
264 
FDA approves Lutathera for some pediatric patients
AuntMinnie
MAY 1, 2024
Food and Drug Administration (FDA) has approved Novartis' Lutathera (lutetium-177 [Lu-177]) DOTATATE radiopharmaceutical for treatment of pediatric patients who are 12 years old and older with somatostatin receptor (SSTR)-positive gastroentropancreatic neuroendocrine tumors (GEP-NETs).
CMS' MPFS 2025 final rule includes colorectal cancer screening
AuntMinnie
NOVEMBER 1, 2024
After many years of advocacy by the American College of Radiology, the Centers for Medicare and Medicaid Services (CMS) will cover CT colonography (CTC) for colorectal cancer (CRC) screening beginning January 1," the college wrote. The ACR lauded the CMS for the colorectal cancer screening coverage.
Meet the Minnies 2024 finalists
AuntMinnie
OCTOBER 25, 2024
Who made it to the final round in the 2024 edition of the Minnies, AuntMinnie.com 's event recognizing excellence in radiology? Most Influential Radiology Researcher Erik Middlebrooks, MD, Mayo Clinic, Jacksonville, FL Erik Middlebrooks, MD. Most Effective Radiology Educator Francis Deng, MD, Johns Hopkins Medicine Francis Deng, MD.
Nuclear Medicine 358
358 
Perspective Therapeutics Announces Exclusive License Agreement with Mayo Clinic for New Radiopharmaceutical Platform for Prostate Cancer Treatment
Imaging Technology
JANUARY 5, 2024
This leading radiopharmaceutical platform provides detailed PET imaging-based diagnosis and dosimetry using long-lived copper-64 ( 64 Cu) for imaging and alpha-particle targeted RPT using lead-212 ( 212 Pb). milla1cf Fri, 01/05/2024 - 11:21 January 5, 2024 — Perspective Therapeutics, Inc.
Anderson wins SNMMI's Georg Charles de Hevesy Nuclear Pioneer award
AuntMinnie
JUNE 9, 2024
Welch Award in 2012; the Distinguished Investigator Award from the Academy of Radiology Research in 2014; SNMMI's Paul C. She has co-authored more than 200 articles, focusing on developing radiopharmaceuticals for oncological imaging and therapy, the society said.
Nuclear Medicine 246
246 
Pneumonia on CT? Consider additional imaging so as not to miss cancer
AuntMinnie
DECEMBER 8, 2023
Suspicion of malignancy may be prompted by avid uptake of the radiopharmaceutical FDG on PET/CT imaging, according to study results delivered on November 27 at the RSNA meeting. Accurate diagnosis of organizing pneumonia is confounded by the co-existence of [the condition] with lung malignancies," Kim said.
Imaging 309
309 
Life Molecular Imaging, Sofie add Neuraceq availability out of Ohio
AuntMinnie
APRIL 4, 2024
Life Molecular Imaging (LMI) and Sofie Biosciences have begun offering the Neuraceq ( florbetaben F-18) PET radiotracer produced at Sofie's radiopharmaceutical manufacturing site in Cleveland, Ohio. With this expansion, LMI continues driving commercial sales of Neuraceq around the U.S.
The rise of theranostics: Part 1 -- Gaining momentum
AuntMinnie
MARCH 26, 2024
Food and Drug Administration's (FDA) approvals of radiopharmaceuticals for neuroendocrine tumors and then for prostate cancer, theranostics has picked up momentum in clinical practice, propelled by encouraging research. Since 2013 we've had several more radiopharmaceutical therapies get FDA approval. Since the U.S.
Nuclear Medicine 306
306 
AI helps predict kidney function decline in Lu-177 patients
AuntMinnie
FEBRUARY 24, 2025
An open-source AI tool can help predict renal function decline in prostate cancer patients undergoing lutetium-177 (Lu-177) radiopharmaceutical therapy, according to a study published February 25 in Radiology.
Nuclear Medicine at the Centre of Radiology and Radiopharmaceuticals
Open Medscience
MARCH 22, 2024
The post Nuclear Medicine at the Centre of Radiology and Radiopharmaceuticals appeared first on Open Medscience. Nuclear medicine and the future of precise, personalised care in diagnosing and treating diseases.
IMV: Nuclear medicine procedure volumes decrease
AuntMinnie
APRIL 15, 2024
According to the report, this year 14% of nuclear medicine sites are currently performing theranostics procedures, with the top two radiopharmaceuticals used being Y-90 microspheres and iodine-131. Changes in nuclear medicine procedure volumes between 2021 and 2023 Facility Type Volume change since 2021 2-year CAGR Hospitals -10.7% -5.5%
Nuclear Medicine 279
279 
NorthStar and Curadh MTR enter strategic partnership
AuntMinnie
JANUARY 3, 2024
NorthStar Medical Radioisotopes and Chester Springs, PA-based Curadh MTR have entered a strategic collaboration agreement to develop radiopharmaceuticals for the treatment of primary and metastatic solid tumors.
FCH-PET/CT superior to MIBI-SPECT/CT for guiding parathyroid surgery
AuntMinnie
JUNE 20, 2024
We expect these findings to contribute to the marketing authorization of this existing radiopharmaceutical for a new clinical indication,” it concluded. Additionally, the tracer was found useful in 2014 in patients with PHPT. This study further supports its use in these patients, the team wrote. “We The full study is available here.
SNMMI: AI PET/CT tool accurately segments tumors for multiple cancers
AuntMinnie
JUNE 10, 2024
“The approach may also assist in the early management of patients with advanced, end-stage disease by identifying appropriate treatment regimens and predicting response to therapies, such as radiopharmaceutical therapy.” Automatic cancer detection and characterization can make way for early treatment and better patient outcomes.
Nuclear Medicine 257
257 
Alpha-9 Oncology, NorthStar Medical Radioisotopes ink supply agreement
AuntMinnie
JANUARY 8, 2024
NorthStar will be one of the first commercial-scale producers of actinium-225 for clinical research and commercial radiopharmaceutical therapy, Alpha-9 said. Alpha-9 Oncology and NorthStar Medical Radioisotopes have entered into a supply agreement under which NorthStar will provide Alpha-9 with actinium-225.
Medical 130
130 
Evans named Gambhir Trailblazer Award recipient
AuntMinnie
JUNE 10, 2024
Evans, a professor in the Department of Radiology and Biomedical Imaging at the University of California, San Francisco, was recognized for his work in biomarker discovery and radiopharmaceutical development. He will be honored at the SNMMI's annual meeting in Toronto.
Nuclear Medicine 100
100 
Imaging societies' reactions mixed on finalized MPFS, HOPPS rules
AuntMinnie
NOVEMBER 4, 2024
Radiological societies have mixed views on the U.S. reduction in average Medicare payment rates compared with 2024, the CMS has estimated there will be a 0% change to reimbursement for radiology, nuclear medicine, and radiation oncology. Although the 2025 MPFS calls for an overall 2.9% Although the 2025 MPFS calls for an overall 2.9%
UCSF, GE HealthCare Launch Joint Research Program to Drive Innovation
Imaging Technology
JANUARY 27, 2025
Our collaboration with GE HealthCare brings a practical focus on addressing well-defined clinical objectives, said Sharmila Majumdar, PhD, Research Vice Chair in the UCSF Department of Radiology & Biomedical Imaging. The team aims to standardize processes for new approaches, such as visualization of alpha-emitting radiopharmaceuticals.
Healthcare 59
59 
Blue Earth Diagnostics, a Bracco Company, Appoints Marco Campione as Chief Executive Officer
Imaging Technology
JULY 9, 2024
I congratulate Marco Campione on this CEO appointment and we look forward to drawing upon his strategic, operational and broad general business expertise as we increase our global leadership throughout the diagnostic radiopharmaceutical industry,” said Fulvio Renoldi Bracco, CEO of Bracco Imaging. Bracco Imaging S.p.A., Bracco Imaging S.p.A.,
Diagnostic 105
105 
Will new CPT codes spark utilization of quantitative MRI?
AuntMinnie
JANUARY 30, 2024
Lipton is a professor of radiology at Columbia University’s Vagelos College of Physicians and Surgeons and an affiliate professor of biomedical engineering at Columbia University. "In As such, radiopharmaceuticals consisting of a TSPO ligand coupled to a PET radioisotope serve as effective imaging agents for neuroinflammation.
MRI 263
263 
Blue Earth Therapeutics Announces Publication of Results from Independent Clinical Experience with 177Lu-rhPSMA-10.1 in Treatment of Metastatic Castrate Resistant Prostate Cancer
Imaging Technology
FEBRUARY 21, 2024
milla1cf Wed, 02/21/2024 - 18:58 February 21, 2024 — Blue Earth Therapeutics , a Bracco company and emerging leader in the development of innovative next generation therapeutic radiopharmaceuticals, is pleased to share the publication of promising early clinical data with 177Lu-rhPSMA-10.1 177Lu-rhPSMA-10.1
Clinic 104
104 
The rise of theranostics: Part 2 -- Moving into communities
AuntMinnie
APRIL 4, 2024
A decade ago, only a few radiopharmaceutical agents were used to help treat cancer patients. Hope, vice chair of clinical operations and strategy in the UCSF department of radiology, established the radioligand therapy group at the university. However, few freestanding theranostics centers exist today.
Nuclear Medicine 222
222 
Let's personalize your content